PL1973545T3 - Bicykliczne Związki Heteroarylowe - Google Patents

Bicykliczne Związki Heteroarylowe

Info

Publication number
PL1973545T3
PL1973545T3 PL06845939T PL06845939T PL1973545T3 PL 1973545 T3 PL1973545 T3 PL 1973545T3 PL 06845939 T PL06845939 T PL 06845939T PL 06845939 T PL06845939 T PL 06845939T PL 1973545 T3 PL1973545 T3 PL 1973545T3
Authority
PL
Poland
Prior art keywords
bicyclic heteroaryl
heteroaryl compounds
compounds
bicyclic
heteroaryl
Prior art date
Application number
PL06845939T
Other languages
English (en)
Inventor
Dong ZOU
Wei-Sheng Huang
R Mathew Thomas
Jan Antoinette C Romero
Jiwei Qi
Yihan Wang
Xiaotian Zhu
William C Shakespeare
Rajeswari Sundaramoorthi
Chester A Metcalf Iii
David C Dalgarno
Tomi K Sawyer
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1973545(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Publication of PL1973545T3 publication Critical patent/PL1973545T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL06845939T 2005-12-23 2006-12-22 Bicykliczne Związki Heteroarylowe PL1973545T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75400005P 2005-12-23 2005-12-23
US75396205P 2005-12-23 2005-12-23
US75608906P 2006-01-03 2006-01-03
US79847206P 2006-05-08 2006-05-08
US83319106P 2006-07-25 2006-07-25
PCT/US2006/048758 WO2007075869A2 (en) 2005-12-23 2006-12-22 Bicyclic heteroaryl compounds
EP06845939A EP1973545B1 (en) 2005-12-23 2006-12-22 Bicyclic heteroaryl compounds

Publications (1)

Publication Number Publication Date
PL1973545T3 true PL1973545T3 (pl) 2013-05-31

Family

ID=38218600

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12169710T PL2495016T3 (pl) 2005-12-23 2006-12-22 Bicykliczne związki heteroarylowe
PL06845939T PL1973545T3 (pl) 2005-12-23 2006-12-22 Bicykliczne Związki Heteroarylowe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL12169710T PL2495016T3 (pl) 2005-12-23 2006-12-22 Bicykliczne związki heteroarylowe

Country Status (21)

Country Link
US (10) US8114874B2 (pl)
EP (4) EP1973545B1 (pl)
JP (3) JP5200939B2 (pl)
KR (1) KR101436303B1 (pl)
CN (1) CN103044432B (pl)
AU (1) AU2006331673B2 (pl)
CA (1) CA2634923C (pl)
CY (3) CY1113907T1 (pl)
DK (2) DK2495016T3 (pl)
EA (2) EA027573B1 (pl)
ES (2) ES2403206T3 (pl)
FR (1) FR13C0069I2 (pl)
HU (2) HUE047422T2 (pl)
IL (2) IL191938A (pl)
LT (1) LT2495016T (pl)
LU (1) LU92327I2 (pl)
MX (2) MX343042B (pl)
PL (2) PL2495016T3 (pl)
PT (2) PT2495016T (pl)
SI (1) SI2495016T1 (pl)
WO (1) WO2007075869A2 (pl)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1940843A4 (en) 2005-08-11 2010-09-15 Ariad Pharma Inc UNSATURATED HETEROCYCLIC DERIVATIVES
DK2495016T3 (da) 2005-12-23 2019-12-16 Ariad Pharma Inc Bicykliske heteroarylforbindelser
EA200870514A1 (ru) 2006-05-08 2009-04-28 Ариад Фармасьютикалз, Инк. Ацетиленовые гетероарильные соединения
US8278307B2 (en) 2006-05-08 2012-10-02 Ariad Pharmaceuticals, Inc. Monocyclic Heteroaryl compounds
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
US8558002B2 (en) 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
WO2008061236A2 (en) 2006-11-16 2008-05-22 Allergan, Inc. Sulfoximines as kinase inhibitors
US8143410B2 (en) 2006-11-16 2012-03-27 Allergan, Inc. Kinase inhibitors
MY188335A (en) 2006-11-22 2021-11-30 Incyte Holdings Corp Imidazotriazines and imidazopyrimidines as kinase inhibitors
EP2070929A1 (en) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
BRPI0912882A2 (pt) 2008-05-21 2017-05-16 Incyte Corp sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
FR2933981A1 (fr) * 2008-07-18 2010-01-22 Sanofi Aventis NOUVEAUX DERIVES IMIDAZO°1,2-a!PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
WO2010017047A1 (en) * 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
WO2010056311A1 (en) 2008-11-12 2010-05-20 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
EP2762142A1 (en) * 2009-10-30 2014-08-06 ARIAD Pharmaceuticals, Inc. Compositions for treating cancer
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP5714030B2 (ja) 2010-02-03 2015-05-07 インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
US8846671B2 (en) 2010-07-01 2014-09-30 Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
CN101885722B (zh) * 2010-07-01 2013-07-24 中国科学院广州生物医药与健康研究院 杂环炔苯类化合物及其药用组合物和应用
CN103502217B (zh) * 2011-01-21 2015-11-25 太阳医药高级研究有限公司 包含酪氨酸激酶抑制剂的二芳基乙炔酰肼
WO2012127030A1 (en) * 2011-03-23 2012-09-27 Proteosys Ag Arylpiperazines as neuroprotective agents
JP2014513078A (ja) * 2011-04-07 2014-05-29 アリアド・ファーマシューティカルズ・インコーポレイテッド パーキンソン病の治療方法及び治療用組成物
CN103582478A (zh) * 2011-04-07 2014-02-12 阿里亚德医药股份有限公司 治疗神经退行性疾病的方法和组合物
RU2477723C2 (ru) * 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
JP2015514802A (ja) * 2012-04-25 2015-05-21 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｒａｆキナーゼ媒介疾患用の方法及び組成物
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
CN103421005A (zh) * 2012-05-16 2013-12-04 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
US8859553B2 (en) * 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
US20150291594A1 (en) * 2012-08-14 2015-10-15 Concert Pharmaceuticals, Inc. Deuterated Ponatinib
CN103664787B (zh) * 2012-09-17 2015-09-09 南京圣和药业股份有限公司 炔杂芳环化合物及其应用
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
CN103848829B (zh) 2012-11-28 2017-04-12 南京圣和药业股份有限公司 杂芳基炔烃化合物及其应用
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
US20140343282A1 (en) 2013-05-16 2014-11-20 Apicore, Llc Processes for making ponatinib and intermediates thereof
US9725454B2 (en) 2013-07-04 2017-08-08 Sandoz Ag Crystalline forms of ponatinib hydrochloride
CN104341416B (zh) * 2013-07-31 2017-03-29 南京圣和药业股份有限公司 蛋白酪氨酸激酶抑制剂及其应用
GB2518873A (en) * 2013-10-03 2015-04-08 Agency Science Tech & Res Bicyclic alkyne derivatives and uses thereof
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
CN105849099B (zh) 2013-10-18 2020-01-17 达纳-法伯癌症研究所股份有限公司 周期蛋白依赖性激酶7(cdk7)的多环抑制剂
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN104650086A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 盐酸帕纳替尼化合物
WO2015085971A1 (en) 2013-12-09 2015-06-18 Zentiva, K.S. Hydrobromide salt of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide
WO2015085972A1 (en) 2013-12-09 2015-06-18 Zentiva, K.S. NOVEL SALTS OF 3-(2-IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-[4-[(4-METHYL- 1-PIPERAZINYL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE
WO2015085973A1 (en) 2013-12-09 2015-06-18 Zentiva, K.S. Modifications of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide hydrochloride salt
CN104496994B (zh) * 2014-01-06 2016-12-07 广东东阳光药业有限公司 一种炔类杂芳基化合物的新晶型
GB2522226A (en) * 2014-01-17 2015-07-22 Agency Science Tech & Res Heteroaryl alkyne derivatives and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9765072B2 (en) 2014-06-06 2017-09-19 Natco Pharma Limited 1H-1,8-naphthyridin-2ones as anti proliferative compounds
KR102485100B1 (ko) 2014-07-17 2023-01-04 선샤인 레이크 파르마 컴퍼니 리미티드 치환된 우레아 유도체 및 이의 약제학적 용도
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN105837575B (zh) * 2015-01-13 2019-01-15 四川大学 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
CN106167491A (zh) * 2015-05-19 2016-11-30 重庆大学 一种有效抑制肺癌转移的化合物及其应用
WO2016201203A1 (en) * 2015-06-11 2016-12-15 Apicore Us Llc Processes for making ponatinib and intermediates thereof
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
AU2016321218A1 (en) * 2015-09-09 2018-03-29 Warren C. Lau Methods, compositions, and uses of novel fyn kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CA3016196A1 (en) 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
US10870647B2 (en) 2016-06-20 2020-12-22 Daegu-Gyeongbuk Medical Innovation Foundation Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer
WO2018002958A1 (en) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
US20210006178A1 (en) * 2016-09-29 2021-01-07 Transportation Ip Holdings, Llc Harmonic distortion reduction system for converters connected to a common bus
US10221184B2 (en) 2017-01-20 2019-03-05 Apicore Us Llc Polymorphs of ponatinib hydrochloride
CA3056348A1 (en) 2017-03-15 2018-09-20 Sun Pharma Advanced Research Company Limited Novel amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n'-(2-chloro-6-methyl-benzoyl) hydrazide
AU2018235447B2 (en) 2017-03-15 2021-12-09 Sun Pharma Advanced Research Company Limited Novel amorphous dispersion of cyclopropanecarboxylic acid (5-{5-[N'-(2chloro-6-methylbenzoyl)hydrazinocarbonyl]-2-methyl-phenylethynyl}-pyridin-2-yl)amide
CA3067271A1 (en) 2017-06-20 2018-12-27 Apotex Inc. Crystalline forms of ponatinib hydrochloride
JP7024960B2 (ja) * 2017-10-04 2022-02-24 国立大学法人京都大学 Ｂｃｒ－Ａｂｌタンパク質イメージング用分子プローブ
EP3781568A1 (en) 2018-06-22 2021-02-24 Johnson Matthey Public Limited Company Form of ponatinib
CA3099763A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
CN110194772B (zh) * 2018-07-02 2022-04-05 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基（杂）芳环类化合物
EP3808746B1 (en) * 2018-07-17 2023-08-02 Shenzhen TargetRx, Inc. N-[3-[2-[8-[(1h-pyrazol-4-yl)amino]imidazo[1,2-a]pyrazin-3-yl]ethynyl]phenyl]-benzamide derivatives and related compounds as protein kinase inhibitors for the treatment of cancer
JP7474752B2 (ja) * 2018-09-12 2024-04-25 パデュー リサーチ ファウンデイション キナーゼ阻害剤としてのアルキニルニコチンアミド化合物
US11427591B2 (en) 2018-10-17 2022-08-30 Insilico Medicine Ip Limited Kinase inhibitors
IL282737B2 (en) 2018-11-01 2025-05-01 Syros Pharmaceuticals Inc Cyclin-dependent kinase 7 (CDK7) inhibitors
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
CA3124330A1 (en) 2018-12-21 2020-06-25 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2020214999A1 (en) * 2019-04-17 2020-10-22 Emory University Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases
US12398142B2 (en) 2019-04-17 2025-08-26 Emory University Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases
WO2020223235A1 (en) 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
KR102205619B1 (ko) 2019-06-12 2021-01-21 한국과학기술연구원 신규한 인다졸 유도체 화합물 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN111004240B (zh) * 2019-12-13 2020-12-01 山东铂源药业有限公司 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
US20230219934A1 (en) * 2020-06-24 2023-07-13 Purdue Research Foundation 2,3-disubstituted pyrido[3,4-b]pyrazine-containing compounds as kinase inhibitors
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US20220289756A1 (en) * 2021-03-11 2022-09-15 Wai Kit Pang Compounds and compositions as inhibitors of protein kinases
CN112778207A (zh) * 2021-03-19 2021-05-11 海南鑫开源医药科技有限公司 一种盐酸尼洛替尼原料药杂质及其制备方法
EP4324833A4 (en) 2021-04-13 2025-07-23 Shenzhen Newdel Biotech Co Ltd ALKYNYLPHENYLBENZAMIDE COMPOUND AND ITS USE
WO2022225972A1 (en) * 2021-04-19 2022-10-27 Oregon Health & Science University Compounds with improved cardiac safety for the treatment of cancer and neurodegenerative disorders
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
EP4646417A1 (en) * 2023-01-13 2025-11-12 Shenzhen Newdel Biotech Co., Ltd. Salts and crystalline forms of compound a, methods of preparation, and uses thereof
WO2025253311A1 (en) 2024-06-04 2025-12-11 Hetero Labs Limited 1,2-dicarboxamide compounds as kinase inhibitors

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US5099057A (en) 1987-10-19 1992-03-24 The Dow Chemical Company Process for the preparation of ar-amino-para-arenediols
US5099067A (en) 1988-08-05 1992-03-24 Northwestern University Use of ammonium formate as a hydrogen transfer reagent for reduction of chiral nitro compounds with retention of configuration
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
EP0444549B1 (en) 1990-03-01 1995-01-25 Takeda Chemical Industries, Ltd. Imidazopyridazines their production and use
DE59608203D1 (de) 1995-05-09 2001-12-20 Basf Ag PYRAZOLO- 1,5a]-PYRIMIDINE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP4903963B2 (ja) 1999-11-08 2012-03-28 シェーリング コーポレイション Ｎ−（４−ヒドロキシ−フェニル）−ｎ’−（４’−アミノフェニル）−ピペラジンを調製するためのプロセス
US6420365B1 (en) 2000-01-18 2002-07-16 Neurogen Corporation Imidazopyridines and related derivatives as selective modulators of bradykinin B2 receptors
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE10019714A1 (de) 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
EP1301511A2 (en) 2000-07-14 2003-04-16 Bristol-Myers Squibb Pharma Company IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE10117184A1 (de) 2001-04-05 2002-10-17 Gruenenthal Gmbh Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen
DE10117183A1 (de) 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
WO2002096933A1 (en) 2001-05-30 2002-12-05 Novartis Ag 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
IL159811A0 (en) * 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
DE60220296T2 (de) 2001-09-04 2008-01-17 Sumitomo Chemical Co., Ltd. IMIDAZO(1,2-a)PYRIMIDINE UND DIESE ENTHALTENDE FUNGIZIDZUSAMMENSETZUNGEN
US7570980B2 (en) 2002-09-11 2009-08-04 Becton, Dickinson And Company Apparatus and method for monitoring blood glucose levels including convenient display of blood glucose value average and constituent values
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
KR20050008691A (ko) 2002-04-19 2005-01-21 셀룰러 지노믹스 아이엔씨 이미다조[1,2-ａ]피라진-8-일 아민, 그의 제조방법 및사용방법
AU2003242131A1 (en) * 2002-06-05 2003-12-22 Institute Of Medicinal Molecular Design, Inc. Immunity-related protein kinase inhibitors
AU2003252509A1 (en) 2002-07-29 2004-02-16 Sumitomo Chemical Takeda Agro Company, Limited NOVEL PROCESS FOR PRODUCING IMIDAZO(1,2-b)PYRIDAZINE DERIVATIVE
DE10246890A1 (de) 2002-10-08 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-alpyridin-3-yl-methylamine
DE10247269A1 (de) 2002-10-10 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine
AR041992A1 (es) * 2002-11-06 2005-06-08 Smithkline Beecham Corp Compuesto de piridinil benzoheterociclico, composicion farmaceutica que lo comprende y su uso para prepararla
GB0230089D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
WO2005030218A1 (en) 2003-09-24 2005-04-07 Wyeth Holdings Corporation 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agent
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
KR20060110307A (ko) 2003-11-28 2006-10-24 노파르티스 아게 단백질 키나아제 의존성 질환의 치료에서의 디아릴 우레아유도체
AU2004296242A1 (en) 2003-12-05 2005-06-23 Biovitrum Ab Improved synthesis of 2-substituted adenosines
DE602004018193D1 (de) * 2003-12-24 2009-01-15 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
WO2005060969A1 (en) * 2003-12-24 2005-07-07 Astrazeneca Ab Pyrimidines with tie2 (tek) activity
PE20051089A1 (es) 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
BRPI0508790A (pt) * 2004-04-07 2007-09-04 Applied Research Systems ácido carboxìlicos, uso de um ácido carboxìlico, composto farmacêutico, método de preparação de ácido carboxìlico e composto intermediário
DE102004021716A1 (de) 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
CA2573185A1 (en) * 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
PT1863818E (pt) * 2005-03-23 2010-04-09 Hoffmann La Roche Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2
US20080194552A1 (en) 2005-03-31 2008-08-14 Astrazeneca Ab Aminopyrimidine Derivatives With Tie2 Inhibiting Activity
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
EP1940843A4 (en) 2005-08-11 2010-09-15 Ariad Pharma Inc UNSATURATED HETEROCYCLIC DERIVATIVES
CN101389338B (zh) * 2005-12-23 2013-06-26 阿里亚德医药股份有限公司 双环杂芳基化合物
DK2495016T3 (da) 2005-12-23 2019-12-16 Ariad Pharma Inc Bicykliske heteroarylforbindelser
EA200870514A1 (ru) 2006-05-08 2009-04-28 Ариад Фармасьютикалз, Инк. Ацетиленовые гетероарильные соединения
US8278307B2 (en) 2006-05-08 2012-10-02 Ariad Pharmaceuticals, Inc. Monocyclic Heteroaryl compounds
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
WO2010124047A1 (en) 2009-04-23 2010-10-28 Wyeth Llc Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mglur5)
US8461851B2 (en) 2009-06-08 2013-06-11 University Of Hawaii Systems for transverse electromagnetic mode in-situ soil testing
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
EP2762142A1 (en) 2009-10-30 2014-08-06 ARIAD Pharmaceuticals, Inc. Compositions for treating cancer
CN103582478A (zh) 2011-04-07 2014-02-12 阿里亚德医药股份有限公司 治疗神经退行性疾病的方法和组合物
JP5300939B2 (ja) * 2011-08-25 2013-09-25 安田工業株式会社 仕上加工用工具を用いた加工方法
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Also Published As

Publication number Publication date
ES2403206T3 (es) 2013-05-16
EA034598B1 (ru) 2020-02-25
LT2495016T (lt) 2020-02-10
IL191938A0 (en) 2009-08-03
HUS1300078I1 (hu) 2018-11-28
FR13C0069I1 (fr) 2014-01-17
PT1973545E (pt) 2013-02-11
JP5200939B2 (ja) 2013-06-05
LU92327I9 (pl) 2019-01-16
CY2013044I2 (el) 2015-11-04
JP6604739B2 (ja) 2019-11-13
FR13C0069I2 (fr) 2014-04-18
PL2495016T3 (pl) 2020-06-01
EP1973545A2 (en) 2008-10-01
KR20080081191A (ko) 2008-09-08
CY1113907T1 (el) 2015-11-04
EP2495016B1 (en) 2019-10-16
PT2495016T (pt) 2019-12-16
US20220081440A1 (en) 2022-03-17
KR101436303B1 (ko) 2014-09-02
JP5790629B2 (ja) 2015-10-07
CN103044432B (zh) 2016-08-03
US20200231588A1 (en) 2020-07-23
WO2007075869A3 (en) 2007-11-29
EP3747441A1 (en) 2020-12-09
US20250361232A1 (en) 2025-11-27
SI2495016T1 (sl) 2020-04-30
JP2013064004A (ja) 2013-04-11
BRPI0621098A2 (pt) 2013-04-02
US20070191376A1 (en) 2007-08-16
EP3417912B1 (en) 2020-08-12
US20160368917A1 (en) 2016-12-22
US8470851B2 (en) 2013-06-25
CY2013044I1 (el) 2015-11-04
CA2634923C (en) 2015-05-05
CY1122646T1 (el) 2020-10-14
US20120135986A1 (en) 2012-05-31
EA201790678A1 (ru) 2017-12-29
MX343042B (es) 2016-10-21
LU92327I2 (fr) 2014-02-05
WO2007075869A2 (en) 2007-07-05
US20130231337A1 (en) 2013-09-05
US9029533B2 (en) 2015-05-12
EP2495016A1 (en) 2012-09-05
DK1973545T3 (da) 2013-02-25
CA2634923A1 (en) 2007-07-05
US20190031656A1 (en) 2019-01-31
MX2008008152A (es) 2008-09-12
US20130196979A1 (en) 2013-08-01
EP1973545A4 (en) 2010-03-10
US8114874B2 (en) 2012-02-14
EP1973545B1 (en) 2013-01-30
US9278971B2 (en) 2016-03-08
JP2015147796A (ja) 2015-08-20
US8778942B2 (en) 2014-07-15
HUE047422T2 (hu) 2020-04-28
US20140288082A1 (en) 2014-09-25
AU2006331673A1 (en) 2007-07-05
CN103044432A (zh) 2013-04-17
ES2761180T3 (es) 2020-05-19
EA200870116A1 (ru) 2009-10-30
EP3417912A1 (en) 2018-12-26
IL239445A0 (en) 2015-07-30
IL239445A (en) 2017-02-28
JP2009521462A (ja) 2009-06-04
DK2495016T3 (da) 2019-12-16
AU2006331673B2 (en) 2013-02-28
EA027573B1 (ru) 2017-08-31
IL191938A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
IL239445A (en) Troueryl compounds in cyclic
IL181848A0 (en) Substituted bicyclic imidazo-3-yl-amine compounds
GB0503962D0 (en) Compounds
GB0502418D0 (en) Compounds
SI1973545T1 (sl) Spojine bicikličnega heteroarila
GB0502316D0 (en) Compounds
GB0502310D0 (en) Compounds
GB0505084D0 (en) Compounds
GB0516379D0 (en) Compounds
AP2007004220A0 (en) Motilide compounds
GB0505086D0 (en) Compounds
EP1961754A4 (en) BICYCLIC HETEROCYCLIC COMPOUND
GB0506467D0 (en) Compounds
EP1907385A4 (en) LINKS
GB0505509D0 (en) Compounds
GB0505735D0 (en) Compounds
GB0501985D0 (en) Compounds
GB0503145D0 (en) Compounds
GB0505085D0 (en) Compounds
GB0501984D0 (en) Compounds
EP1867650A4 (en) HYDROXYMETHYLBORVERBINDUNGEN
GB0500882D0 (en) Compounds
GB0502543D0 (en) Compounds
GB0500890D0 (en) Compounds
GB0500892D0 (en) Compounds